CAR-NK Targeted CD19 for r/r B-cell Malignancies

Adult Relapsed/Refractory B-cell Hematologic Malignancies Clinical Trial

Official title: Early Clinical Study of Allogenic CAR-NK Targeted CD19 (JD010) in the Treatment of Adult Relapsed or Refractory B-cell Malignancies

Status Recruiting

Clinical Trial Summary

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of JD010 in adult patients with relapsed or refractory B cell hematologic malignancies. JD010 injection is a CD19-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) derived from a healthy donor

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Neoplasms

• NCT number: NCT05645601
• Study type: Interventional
• Source: Affiliated Hospital to Academy of Military Medical Sciences
• Contact: Liangding Hu, Dr
• Phone: +86 01066947171
• Email: huliangding@sohu.com
• Status: Recruiting
• Phase: Phase 1
• Start date: December 1, 2022
• Completion date: December 30, 2024